Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGMA: Spironolactone in Atherosclerosis and Type 2 Diabetes
NCT02169089Phase 4Completed
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Jan 2016
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of spironolactone in atherosclerosis, sponsored by University Hospitals Cleveland Medical Center. Started Jan 2016; status: completed.
02
Drugs
spironolactone
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02169089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169089.